Endothelial-Mesenchymal Transition in COVID-19 lung lesions.
CD31
COVID-19
Diffuse alveolar damage
Endothelial-Mesenchymal Transition
Fibrosis
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
18
12
2020
revised:
22
03
2021
accepted:
22
03
2021
pubmed:
16
4
2021
medline:
21
5
2021
entrez:
15
4
2021
Statut:
ppublish
Résumé
Sars-Cov-2 infection is still a healthcare emergency and acute respiratory distress failure with Diffuse Alveolar Damage (DAD) features is the main causes of patients' death. Pathogenic mechanisms of the disease are not clear yet, but new insights are necessary to improve therapeutic management, to prevent fatal irreversible multi-organ damage and to adequately follow up those patients who survive. Here we investigated, by histochemistry and immunohistochemistry, a wide number of mapped lung specimens taken from whole body autopsies of 7 patients dead of COVID-19 disease. Our data confirm morphological data of other authors, and enlarge recent reports of the literature suggesting that Endothelial-Mesenchymal Transition might be central to COVID-19 lung fibrosing lesions. Furthermore, based upon recent acquisition of new roles in immunity and vascular pathology of the CD31 molecule, we hypothesize that this molecule might be important in the development and treatment of COVID-19 pulmonary lesions. These preliminary findings need further investigations to shed light on the complexity of Sars-Cov-2 disease.
Identifiants
pubmed: 33857718
pii: S0344-0338(21)00080-7
doi: 10.1016/j.prp.2021.153419
pmc: PMC7997691
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153419Informations de copyright
Copyright © 2021 Elsevier GmbH. All rights reserved.
Références
EBioMedicine. 2020 Nov;61:103104
pubmed: 33158808
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
J Cell Sci. 2013 Jun 1;126(Pt 11):2343-52
pubmed: 23761922
Ann Rheum Dis. 2017 May;76(5):924-934
pubmed: 28062404
Cancer Lett. 2018 Aug 10;429:29-40
pubmed: 29746931
Am J Respir Crit Care Med. 2021 Jan 15;203(2):192-201
pubmed: 33217246
Am J Respir Cell Mol Biol. 2010 Aug;43(2):161-72
pubmed: 19767450
Physiology (Bethesda). 2019 Jan 1;34(1):43-55
pubmed: 30540232
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32859681
J Am Coll Cardiol. 2018 Jul 3;72(1):45-57
pubmed: 29957231
Virchows Arch. 2020 Sep;477(3):359-372
pubmed: 32642842
Biomedicines. 2020 Dec 18;8(12):
pubmed: 33352880